EUVIMEDEUVIMED entdecken
ValidierungsstudieMultizentrische Studie

Development and Validation of the JIKEI ‐ YAYOI Score for Predicting Castration Resistance in Metastatic Castration‐Sensitive Prostate Cancer Treated With ARSI ‐Based Doublet Therapy

Fumihiko Urabe iD, Yudai Ishiyama iD, Wataru Fukuokaya iD, Naoki Fujita iD, Hiromi Sato, Takuma Narita iD, Masataka Kubo iD, Takafumi Yanagisawa iD, Kojiro Tashiro iD, Shintaro Narita iD, Tomonori Habuchi, Shingo Hatakeyama iD und 2 weitere

International Journal of Urology · 2026-10 · 33 (10)

DOI: 10.1111/iju.70677 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift International Journal of Urology, online erschienen am 21.10.2026. Verfasst von Fumihiko Urabe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Jikei University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Androgen Receptor Antagonists, Antineoplastic Combined Chemotherapy Protocols, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metastatic castration‐sensitive prostate cancer (mCSPC) is a heterogeneous disease with variable clinical outcomes despite advances in androgen receptor signaling inhibitor (ARSI)‐based therapy. We aimed to develop and externally validate a prognostic model for predicting progression to castration‐resistant prostate cancer (CRPC) in patients with mCSPC.

Methods

This multicenter retrospective study included patients with mCSPC treated with ARSI doublet therapy. The development cohort comprised 388 patients, whereas the external validation cohort included 451 patients. Prognostic factors for CRPC‐free survival (CRPC‐FS) were identified using Cox proportional hazards regression models. A point‐based risk score (JIKEI‐YAYOI score) was derived from regression coefficients. Model performance was evaluated through assessment of discrimination, calibration, and external validation.

Results

In the development cohort, the median CRPC‐FS was 21 months. Grade Group, extent of disease score, hemoglobin, and lactate dehydrogenase were independently associated with CRPC progression and were incorporated into the model. The model demonstrated good discrimination (apparent C‐index, 0.715; optimism‐corrected C‐index, 0.720). The JIKEI‐YAYOI score ranged from 0 to 8, corresponding to a 3‐year CRPC risk of 10.6%–93.2%. Patients were stratified into low‐risk (≤ 2), intermediate‐risk (3–4), and high‐risk (≥ 5) groups, with significantly different CRPC‐FS and overall survival (both p < 0.001). External validation confirmed good discrimination, calibration, and risk stratification.

Conclusions

The JIKEI‐YAYOI score is a simple, clinically applicable tool for predicting progression to CRPC in patients with mCSPC. Using routinely available clinical variables, it enables individualized risk assessment and may support clinical decision‐making regarding surveillance and treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen Receptor AntagonistsAntineoplastic Combined Chemotherapy ProtocolsProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overHumansMaleMiddle AgedDisease ProgressionPrognosisProportional Hazards ModelsRetrospective StudiesRisk AssessmentProstate

Stichwörter der Autor:innen

ARSI‐doubletmetastatic castration‐resistant prostate cancerrisk model

Substanzen

Androgen Receptor Antagonists

Autor:innen und Institutionen

  • Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.
  • Department of Urology, University of Florida, Jacksonville, Florida, USA.
  • Department of Urology, Division of Advanced Blood Purification Therapy, Hirosaki University Graduate School of Medicine, Aomori, Japan.
  • Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.

ORCID-Profile: Fumihiko Urabe, Yudai Ishiyama, Wataru Fukuokaya, Naoki Fujita, Takuma Narita, Masataka Kubo, Takafumi Yanagisawa, Kojiro Tashiro, Shintaro Narita, Shingo Hatakeyama, Takahiro Kimura

Zitieren

APA

Urabe, F., Ishiyama, Y., Fukuokaya, W., Fujita, N., Sato, H., Narita, T., Kubo, M., Yanagisawa, T., Tashiro, K., Narita, S., Habuchi, T., Hatakeyama, S., Kimura, T., & JHA Collaborative Group (2026). Development and Validation of the JIKEI ‐ YAYOI Score for Predicting Castration Resistance in Metastatic Castration‐Sensitive Prostate Cancer Treated With ARSI ‐Based Doublet Therapy. International Journal of Urology, 33(10). https://doi.org/10.1111/iju.70677

Vancouver

Urabe F, Ishiyama Y, Fukuokaya W, Fujita N, Sato H, Narita T, et al. Development and Validation of the JIKEI ‐ YAYOI Score for Predicting Castration Resistance in Metastatic Castration‐Sensitive Prostate Cancer Treated With ARSI ‐Based Doublet Therapy. International Journal of Urology. 2026;33(10). doi:10.1111/iju.70677

BibTeX
@article{Urabe2026,
  author = {Urabe, Fumihiko and Ishiyama, Yudai and Fukuokaya, Wataru and Fujita, Naoki and Sato, Hiromi and Narita, Takuma and Kubo, Masataka and Yanagisawa, Takafumi and Tashiro, Kojiro and Narita, Shintaro and Habuchi, Tomonori and Hatakeyama, Shingo and Kimura, Takahiro and JHA Collaborative Group, JHA Collaborative Group},
  title = {Development and Validation of the JIKEI ‐ YAYOI Score for Predicting Castration Resistance in Metastatic Castration‐Sensitive Prostate Cancer Treated With ARSI ‐Based Doublet Therapy},
  journal = {International Journal of Urology},
  year = {2026},
  volume = {33},
  number = {10},
  doi = {10.1111/iju.70677}
}
Kostenlos starten →